β-cell function and long-term glycemic control in patients newly diagnosed with type 2 diabetes with moderate hyperglycemia after a 6-month course of basal insulin therapy
Authors' conclusion
A 6-month course of basal insulin therapy did not benefit patients newly diagnosed with diabetes with moderate hyperglycemia in terms of insulin sensitivity or insulin secretion.
Study context
- Population
- Patients newly diagnosed with T2D with moderate hyperglycemia32 analysed
- Participants
- 50 patients
- Comparison
- Insulin vs metformin vs sitagliptin
- Primary endpoint
- HbA1c level change
- Follow-up
- 6 months
Primary result
As reported in the abstract
HbA1c change
Insulin
- 2.06
± 1.37 · %
Metformin
−0.43
± 0.32 · %
Sitagliptin
- 1.62
± 0.92 · %
Secondary outcomes
Treat-to-target (HbA1c < 7.0 %) · 6 months
Treat-to-target (HbA1c < 7.0 %) · 6 months
- Not significantly different among the three groups
Insulin secretion and sensitivity indices (Matsuda index, HOMA-IR) · 6 months
- Groups did not differ
Original publication
β-cell function and long-term glycemic control in patients newly diagnosed with type 2 diabetes with moderate hyperglycemia after a 6-month course of basal insulin therapy. Diabetes Res Clin Pract. Published 8 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →